Lux Biosciences declares intent to halt application efforts for uveitis treatment

Lux Biosciences Inc. does not intend to advance its application for regulatory approval of voclosporin for treatment of noninfectious uveitis in the U.S. and Europe, according to a press release from Isotechnika, with whom Lux Biosciences has a license agreement to develop voclosporin for ophthalmic indications.

The company announced that primary endpoints established in phase 3 clinical trials, which were to demonstrate a change from baseline in vitreous haze at 12 weeks or at the time of treatment failure or sooner, were not met, effectively ending their intent to move forward with the drug’s development for uveitis.

Isotechnika, which has developed voclosporin in the area of nephrology, had “granted Lux worldwide rights to develop and commercialize voclosporin for ophthalmic indications in the hope that the expansion of its platform into other medical specialties might help to maximize the drug's full medical and commercial potential,” according to the release.